Negative regulation of natural killer cell in tumor tissue and peripheral blood of oral squamous cell carcinoma

Cytokine

Volumn 76, Issue 2, 2015, Pages 123-130

  Dutta, Anupam ^a   Banerjee, Arunabha ^a   Saikia, Nabajyoti ^b   Phookan, Jyotirmoy ^c   Baruah, Munindra Narayan ^d   Baruah, Shashi ^a  

^a TEZPUR UNIVERSITY   (India)

^b ASSAM MEDICAL COLLEGE   (India)

^c GAUHATI MEDICAL COLLEGE   (India)

^d North East Cancer Hospital and Research Institute ^*  (India)

Author keywords

Cytokine; Cytotoxic T Lymphocyte Associated Antigen 4; Forkhead Box P3; Killer cell immunoglobulin like receptor; Natural killer cell; Oral squamous cell carcinoma

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 21; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SUPPRESSOR CELL; UPREGULATION; BIOSYNTHESIS; BLOOD; GENETICS; IMMUNOLOGY; K562 CELL LINE; MIDDLE AGED; MOUTH TUMOR; PATHOPHYSIOLOGY; SQUAMOUS CELL CARCINOMA;

BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CTLA-4 ANTIGEN; CYTOKINES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; RECEPTORS, KIR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84943665632     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.09.006     Document Type: Article

References (61)

1. Introna M., Mantovani A. Natural killer cells in human solid tumors. Cancer Metastasis Rev. 1983, 2(4):337-350.
2. Zwirner N.W., et al. Cytokine regulation of natural killer cell effector functions. BioFactors 2010, 36(4):274-288.
3. Vilches C., Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu. Rev. Immunol. 2002, 20:217-251.
4. Bjorkstrom N.K., et al. CD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells. Blood 2012, 120(17):3455-3465.
5. Campbell K.S., Purdy A.K. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011, 132(3):315-325.
6. Caligiuri M.A. Human natural killer cells. Blood 2008, 112(3):461-469.
7. Carrington M, Norman P. The KIR Gene Cluster, National Library of Medicine (US), National Center for Biotechnology Information, Bethesda, 2003.
8. Middleton D., Gonzelez F. The extensive polymorphism of KIR genes. Immunology 2010, 129(1):8-19.
9. Moesta A.K., Parham P. Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3. Front. Immunol. 2012, 3(336).
10. Enk J., Mandelboim O. The role of natural cytotoxicity receptors in various pathologies: emphasis on Type I diabetes. Front. Immunol. 2014, 5(4).
11. Noronha L.E., et al. Generation and characterization of monoclonal antibodies to equine NKp46. Vet. Immunol. Immunopathol. 2012, 147(1-2):60-68.
12. Glasner A., et al. Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J. Immunol. 2012, 188(6):2509-2515.
13. Vitale M., et al. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur. J. Immunol. 2014, 44(6):1582-1592.
14. Gazit R., et al. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat. Immunol. 2006, 7(5):517-523.
15. Mandelboim O., et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001, 409(6823):1055-1060.
16. Halfteck G.G., et al. Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J. Immunol. 2009, 182(4):2221-2230.
17. Gur C., et al. The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat. Immunol. 2010, 11(2):121-128.
18. Gur C., et al. Recognition and killing of human and murine pancreatic beta cells by the NK receptor NKp46. J. Immunol. 2011, 187(6):3096-3103.
19. Romee R., et al. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) 2014, 205796:2014.
20. Vivier E., et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331(6013):44-49.
21. Sanctis J.B.D., et al. Secretion of cytokines by natural killer cells primed with interleukin-2 and stimulated with different lipoproteins. Immunology 1997, 90(4):526-533.
22. Lee H.M., et al. A comparative study of the effects of inhibitory cytokines on human natural killer cells and the mechanistic features of transforming growth factor-beta. Cell. Immunol. 2014, 290(1):52-61.
23. + T cells in glioma patients. Neuro Oncol. 2010, 12(1):7-13.
24. Wilson E.B., et al. Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS ONE 2011, 6(9):e22842.
25. Castriconi R., et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(7):4120-4125.
26. Bellone G., et al. Regulation of NK cell functions by TGF-beta 1. J. Immunol. 1995, 155(3):1066-1073.
27. Ghio M., et al. Soluble HLA-I mediated secretion of TGF-beta1 by human NK cells and consequent downregulation of anti-tumor cytolytic activity. Eur. J. Immunol. 2009, 39(12):3459-3468.
28. Szkaradkiewicz A., et al. Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer. J. Biomed. Biotechnol. 2010, 901564:2010.
29. + regulatory T cells. J. Immunol. 2006, 177(2):896-904.
30. Gaur P., et al. Inter-relation of Th1, Th2, Th17 and Treg cytokines in oral cancer patients and their clinical significance. Hum. Immunol. 2014, 75(4):330-337.
31. Brailo V., et al. Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer. Med. Oral Patol. Oral Cir. Bucal 2012, 17(1):e10-e15.
32. Budhu A., Wang X.W. The role of cytokines in hepatocellular carcinoma. J. Leukoc. Biol. 2006, 80(6):1197-1213.
33. Neurath M.F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 2014, 14(5):329-342.
34. Pitanga T.N., et al. Cytokine profiles in sickle cell anemia: Pathways to be Unraveled. Adv. Biosci. Biotechnol. 2013, 4:6-12.
35. Edge S.B., et al. AJCC Cancer Staging Manual 2010, American Joint Committee on Cancer, Chicago. seventh ed.
36. Barnes L., et al. Pathology and Genetics of Head and Neck Tumours 2005, International Agency for Research on Cancer Publications, Lyon.
37. Imbeaud S., et al. Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces. Nucleic Acids Res. 2005, 33(6):e56.
38. -δδCT method. Methods 2001, 25(4):402-408.
39. Farnault L., et al. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin. Dev. Immunol. 2012, 421702:2012.
40. dim natural killer cell subset in patients with cancer. Eur. J. Immunol. 2003, 33(1):119-124.
41. + natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment. Gut 2014, 63(3):515-524.
42. High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology 2012, 56(4):1201-1213.
43. Costello R.T., et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002, 99(10):3661-3667.
44. Sivori S., et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur. J. Immunol. 1999, 29(5):1656-1666.
45. Garcia-Iglesias T., et al. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 2009, 9(186).
46. Nakano Y., et al. Expression of tumor necrosis factor-α and interleukin-6 in oral squamous cell carcinoma. Jpn. J. Cancer Res. 1999, 90(8):858-866.
47. May L.T., et al. Synthesis and secretion of multiple forms of β2 -interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes. J. Biol. Chem. 1998, 263(16):7760-7766.
48. Rak J.W., et al. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. J. Cell. Physiol. 1994, 159(2):245-255.
49. Brailo V., et al. Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer. Med. Oral Patol. Oral Cir. Bucal. 2012, 17(1):e10-e15.
50. SahebJamee M., et al. Salivary concentration of TNFα, IL1α, IL6, and IL8 in oral squamous cell carcinoma. Med. Oral Patol. Oral Cir. Bucal. 2008, 13(5):E292-E295.
51. Rhodus N.L., et al. The feasibility of monitoring NF-kappaB associated cytokines: TNFalpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol. Carcinog. 2005, 44(2):77-82.
52. Groh V., et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419(6908):734-738.
53. + T regulatory lymphocytes. Res. Immunol.: Int. J. 2013, 119348:2013.
54. + Regulatory T cells and for expansion of these cells. J. Immunol. 2007, 178(4):2018-2027.
55. Starska K., et al. Expression of CTLA-4 and Foxp3 in peripheral blood T cells of patients with squamous cell laryngeal carcinoma. Contemp. Oncol. (Pozn) 2013, 17(4):370-377.
56. Jaberipour M., et al. Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol. Oncol. Res. 2010, 16(4):547-551.
57. Pedroza-Pacheco I., et al. Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. Cell Mol. Immunol. 2013, 10(3):222-229.
58. Orentas R.J., et al. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin. Cancer Biol. 2006, 16(2):137-149.
59. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 2005, 202(8):1075-1085.
60. + and NK lymphocytes in the direct cell-to-cell interaction. Clin. Immunol. 2004, 112(3):258-267.
61. Cai L., et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin. Immunol. 2008, 129(3):428-437.